Ask AI
SC ICI Delivery

CE

From IV to SC: Multidisciplinary Strategies for Transforming ICI Delivery to Enhance Patient-Centered Care and Ensure Equitable Access

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: August 04, 2025

Expiration: February 03, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is a benefit reported for subcutaneous ICI vs IV formulation?

2.

Which of the following statements is true regarding the efficacy and safety of SC vs IV ICIs across different tumor types based on data presented from the phase III MK-3475A-D77 and phase Ib/III IMscin001 studies in patients with lung cancer and the phase III CheckMate 67T in patients with renal cell carcinoma?

3.

Your patient will be receiving SC ICI plus chemotherapy for stage IIIB NSCLC. Which of the following should you tell them is an AE experienced by patients receiving an ICI that should be reported to their APP?